Presence of Cx43 in extracellular vesicles reduces the cardiotoxicity of the anti-tumour therapeutic approach with doxorubicin by Martins-Marques, Tania et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=zjev20
Journal of Extracellular Vesicles
ISSN: (Print) 2001-3078 (Online) Journal homepage: https://www.tandfonline.com/loi/zjev20
Presence of Cx43 in extracellular vesicles reduces
the cardiotoxicity of the anti-tumour therapeutic
approach with doxorubicin
Tania Martins-Marques, Maria Joao Pinho, Monica Zuzarte, Carla Oliveira,
Paulo Pereira, Joost P. G. Sluijter, Celia Gomes & Henrique Girao
To cite this article: Tania Martins-Marques, Maria Joao Pinho, Monica Zuzarte, Carla Oliveira,
Paulo Pereira, Joost P. G. Sluijter, Celia Gomes & Henrique Girao (2016) Presence of Cx43 in
extracellular vesicles reduces the cardiotoxicity of the anti-tumour therapeutic approach with
doxorubicin, Journal of Extracellular Vesicles, 5:1, 32538, DOI: 10.3402/jev.v5.32538
To link to this article:  https://doi.org/10.3402/jev.v5.32538
© 2016 Tania Martins-Marques et al. View supplementary material 
Published online: 29 Sep 2016. Submit your article to this journal 
Article views: 354 View Crossmark data
Citing articles: 11 View citing articles 
ORIGINAL RESEARCH ARTICLE
Presence of Cx43 in extracellular vesicles reduces the
cardiotoxicity of the anti-tumour therapeutic approach
with doxorubicin
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Extracellular vesicles (EVs) are major conveyors of biological information, mediating local and systemic cell-
to-cell communication under physiological and pathological conditions. These endogenous vesicles have
been recognized as prominent drug delivery vehicles of several therapeutic cargoes, including doxorubicin (dox),
presenting major advantages over the classical approaches. Although dox is one of the most effective anti-
tumour agents in the clinical practice, its use is very often hindered by its consequent dramatic cardiotoxicity.
Despite significant advances witnessed in the past few years, more comprehensive studies, supporting the
therapeutic efficacy of EVs, with decreased side effects, are still scarce. The main objective of this study was to
evaluate the role of the gap junction protein connexin43 (Cx43) in mediating the release of EV content into
tumour cells. Moreover, we investigated whether Cx43 improves the efficiency of dox-based anti-tumour
treatment, with a concomitant decrease of cardiotoxicity. In the present report, we demonstrate that the
presence of Cx43 in EVs increases the release of luciferin from EVs into tumour cells in vitro and in vivo. In
addition, using cell-based approaches and a subcutaneous mouse tumour model, we show that the anti-tumour
effect of dox incorporated into EVs is similar to the administration of the free drug, regardless the presence of
Cx43. Strikingly, we demonstrate that the presence of Cx43 in dox-loaded EVs reduces the cardiotoxicity of the
drug. Altogether, these results bring new insights into the concrete potential of EVs as therapeutic vehicles and
open new avenues toward the development of strategies that help to reduce unwanted side effects.
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E
xtracellular vesicles (EVs), including exosomes
and microvesicles, are nano-sized particles that
can be released by virtually every cell type into
the extracellular milieu (13). Hence, EVs are found in
several body fluids including saliva, urine, malignant
ascites, and blood, and they are considered important
tools for diagnosis and therapy (3). Because EVs are
able to cross stringent biological barriers and remain

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in circulation without eliciting immune responses, these
vesicles have emerged as excellent candidates for drug
delivery (4,5). Importantly, the therapeutic value of EVs
largely depends upon an efficient uptake and intracellular
processing of deliverable material. Although a few different
models have been proposed to depict the mechanisms
underlying EVcell interaction, the most robust evidence
pointed to endocytosis or membrane fusion of EVs within
target cells (3,6). Recently, we proposed an additional mode
of communication, involving connexin43 (Cx43)-containing
channels. Results from our lab demonstrated that the gap
junction (GJ) protein Cx43, embedded in EV membranes,
forms a channel that facilitates the release of intravesicle con-
tent into recipient cells, likely playing important functions on
selective EV targeting, increased cargo delivery, or both (7).
Mounting lines of evidence established the therapeutic
potential of endogenous membrane-enclosed vesicles,
mostly focused on inflammation and cancer. For example,
curcumin-loaded exosomes were found to confer protection
in mice models of lipopolysaccharide-induced sepsis,
whereas intratumoural delivery of microvesicles carrying
the cytosine deaminase mRNA and protein, in combination
with systemic delivery of a pro-drug, leads to reduced growth
of schwannoma xenografts in vivo (8,9).
Given that cancer cells express a myriad of membrane
receptors that can confer targeting selectivity, EV homing
has been attempted through the use of engineered vesicles
with surface-targeting peptides (4,10,11). This enhanced
tropism is particularly important to mitigate the side
effects of cytotoxic compounds. For example, doxorubicin
(dox) is among the most effective chemotherapeutic agents
used in the clinical practice, with indications for
a wide variety of cancers. Nevertheless, its use has been
limited by the high incidence of acute cardiotoxicity that
arises in about 11% of the patients (12). Consequently, EVs
or liposomal formulations of dox have been considered as
valuable therapeutic alternatives to decrease toxicity to
non-target organs (13,14). Tian et al. demonstrated that
exosomes with surface expression of the internalizing-
RGD peptide (Arg-Gly-Asp); amino acid sequence
CRGDK/RGPD/EC peptide, exogenously loaded with
dox, display enhanced tropism to breast cancer xenografts
and increased therapeutic efficiency (10). Given its potential,
additional studies are required to deeply demonstrate the
efficacy of EVs as dox-carrying agents.
Although it is known that initial stages of tumour
growth involve a downregulation of Cx43, further dis-
semination and colonization of malignant cells require the
presence of Cx43 (15,16). Therefore, we hypothesized that
Cx43 can constitute a target to direct therapeutic vehicles
within specific stages of tumour development. In the
present work, we investigated whether the presence of
Cx43 improves the therapeutic potential of EVs as carriers
of dox, with a concomitant reduction of cardiotoxicity in a
subcutaneous breast cancer mouse model.
Materials and methods
Cell culture and animal models
Human embryonic kidney (HEK)-293 and 4T1luc2 (Perkin
Elmer) cell lines were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) (Life Technologies), supplemen-
ted with 10% foetal bovine serum (FBS, Gibco), penicillin/
streptomycin (100 U/ml:100mg/ml) and 1% GlutaMax
(Life Technologies). Animals were handled according to
European Union guidelines (86/609/EEC), with approval
of the Ethics Committee, Faculty of Medicine, University of
Coimbra. The tumour model was established by subcuta-
neous injection of 0.5106 murine breast 4T1luc2 cells in
opposite flanks of 12-week-old female Swiss nude mice
(Charles River) (17,18). EVs loaded with luciferin and
dox were resuspended in phosphate-buffered saline (PBS)
(10 mg of EVs/20 ml of PBS) and intratumourally (i.t.)
injected. Tumour growth was monitored 5, 8 and 11 days
post-inoculation by bioluminescence imaging (BLI) with
an IVIS Lumina II XR (PerkinElmer), 8 min after intra-
peritoneal (i.p.) injection of D-luciferin (150 mg/kg), with
animals under anaesthesia (100 mg/kg ketamine and 2.5%
chlorpromazine). Images were analysedwith Living Imaging
4.10 (Caliper Life Sciences SA) (19). A region of interest
(ROI) was drawn around the tumour for bioluminescence
quantification. Tumour volumes were assessed with a man-
ual caliper and calculated with the formula (length
width2)/2. Experiments were ended before tumours reach-
ed a 2 cm3 volume endpoint. Animals were sacrificed,
tumours and hearts were harvested, and then they were
embedded in optimum cutting temperature (OCT) matrix
(Tissue-Tek) for cryosectioning, or snap-frozen in liquid
nitrogen for biochemical studies, before storage at 808C.
EV purification
HEK-293 cells expressing Cx43 or not (HEK-293Cx43
and HEK-293Cx43 ) (7) were cultured in EV-depleted
medium, prepared by ultracentrifugation of 50% FBS
(120,000 g, 16 h). Supernatants were diluted to a final
concentration of 10% FBS in DMEM. After 48 h, condi-
tioned medium was collected for EV isolation by dif-
ferential centrifugation at 48C, starting with 10 min at
300 g, and 20 min at 16,500 g. Supernatants were filtered
(0.22 mm filter units, cellulose acetate) and ultracentri-
fuged (120,000 g, 70 min) (20). Pellets were resuspended
in PBS and immediately used for EV loading. On average,
0.5 mg of purified EVs was obtained per 1 million cells.
Transmission electron microscopy (TEM) characteriza-
tion of EVs was performed as described previously (7).
EV loading
Five micrograms of EVs was incubated with 150 mM 1-(4,5-
dimethoxy-2-nitrophenyl)ethyl ester (DMNPE)-caged-D-lu-
ciferin for 1 h, at 378C, protected from light. Luciferin was
released from the DMNPE group by UV-B (365 nm) photol-
ysis (5 min, on ice) using an UV transilluminator (7,21).
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Non-incorporated luciferin was removed using Exosome
Spin Columns (Life Technologies). Luciferin-loaded EVs
were added to 4T1luc2 seeded in 96-well plates, or injected i.t.
into mice, followed by BLI. Ten micrograms of EVs was
mixed with 100 mg of dox (DOXO-cell†) in PBS supple-
mented with 5 mM EDTA, and then the mixture was
electroporated at 35 V and 150 mF using 0.4 cm cuvettes
in a Gene Pulser II electroporator (Bio-Rad) (10,21).
Empty EVs were also electroporated. Non-incorporated
dox was washed out with PBS by using ultracentrifugation
(120,000 g, 70 min). Loaded dox was quantified by fluores-
cence detection in a Biotek Synergy HT microplate reader
(emission, 594 nm; excitation, 480 nm) with Gen 5 software
(BioTek). Fluorescence readings were compared with
a standard curve of free dox. On average, yield of dox
encapsulation was 10%.
Determination of cell viability, proliferation, motility
and colony formation in vitro
4T1luc2 cells were treated with 2mM free dox or dox-loaded
EVs for 24 h, when appropriate. Metabolic activity,
through the 3-(4,5-dimethylthiazol-2-yl)-2.5-diphenyl tet-
razolium bromide (MTT, Sigma) assay (17), and cell
viability, by Trypan blue exclusion or flow cytometry, after
propidium iodide (PI) staining, were performed as de-
scribed previously (22,23). Cell proliferation was assessed
by 5-bromo-2?-deoxyuridine (BrdU) incorporation ac-
cording to the manufacturer’s instructions (Roche Diag-
nostics). Where indicated, cells were treatedwith 0.25 mg/ml
gap26 (Caslo) for 1 h. Staining of ki-67positive cells was
performed by immunofluorescence (1:100, AB16667, Ab-
cam) (24). Images were obtained using an Axio Obser-
ver.Z1 inverted microscope (Zeiss) and analysed with
ImageJ (National Institutes of Health). Cell cycle analysis
was performed by flow cytometry, after PI/RNase staining
(Immunostep) (25). Cell motility was analysed by time-
lapse video microscopy (6 h, 3 min acquisition interval,
using an Axio Observer.Z1 inverted microscope), with the
cells under an atmosphere of 5% CO2 at 378C. Manual cell
tracking analysis was performed with ImageJ (26). For
colony formation assay, cells were treated for 48 h, as
indicated, after which medium was replaced by a drug-free
medium, and cells were allowed to grow for 7 days. At the
end of the experiment, cells were fixed and stained with
crystal violet (Sigma-Aldrich) (27). Microscopy images
were obtained using an Axio Observer.Z1 inverted micro-
scope.
Western blot
Cell and tissue lysates were prepared as described pre-
viously (28). EV pellets were lysed in a non-reducing
loading buffer. Primary antibodies against CD63 (1:500,
AB0047, Sicgen), CD81 (1:250, Sc9158, Santa Cruz
Biotechnology), Cx43 (1:2,500, AB0016, Sicgen), Calnex-
in (1:5,000, AB0041, Sicgen), phosphorylated and total
p44/42 (1:500, 4377S and 9102, Cell Signaling Technology),
Bax (1:250, Sc6236, Santa Cruz Biotechnology) and Bcl2
(1:250, Sc7382, Santa Cruz Biotechnology) were used,
followed by incubation with horseradish peroxidase
conjugated secondary antibodies (1:10,000, Bio-Rad).
Images were visualized in a VersaDoc system (Bio-Rad).
Densitometric quantification was performed in unsatu-
rated images using ImageJ.
Immunofluorescence staining and histology
Immunofluorescence staining of tissue samples (5 mm
cryosections) was carried out as described previously (29).
Fixation was performed with acetone and blocking with
2.5% bovine serum albumin. Primary antibodies against
cyclooxygenase (COX)-2 (1:100, ab15191, Abcam), Hsp27
(1:50, SPA-803, Stressgen) and Cx43 (1:250, AB0016,
Sicgen) were used. Images were collected with an Axio
Observer.Z1 inverted microscope. For haematoxylin and
eosin (HE) and Sirius red (0.1% in saturated aqueous
picric acid) staining, slices were fixed in 4% paraformalde-
hyde (30). Images were collected with an AxioLab.A1
microscope (Zeiss). Quantitative analysis (at least 10
randomly chosen fields) was performed using ImageJ,
including measure of transverse diameter of the myocytes
cut at the level of the nucleus and area of fibrosis.
Statistical analysis
Data were analysed with Prism 7, version 7.0a (GraphPad
Software, Inc.). Statistical significance was assessed by
Student’s t-test or KruskalWallis test, where appropri-
ate. Experimental data were presented as scatterplots
plus mean (31), or as mean9standard error of the mean,
where applicable.
Results
Cx43 mediates the communication between EVs and
tumour cells
In the present work, we hypothesized that Cx43 facilitates
the direct transfer of EV cargo, including cytotoxic
drugs, into tumour cells, thus contributing to improve
the therapeutic potential of EVs. First, we demonstrated
that our preparations of EVs, obtained from HEK-293
cells, containing or not Cx43, EVCx43 or EVCx43
(7,32), are positive for canonical EV markers, such as the
tetraspanins CD63 and CD81 (Fig. 1a), and present
typical size and morphology (Fig. 1b). In addition, the
presence of higher molecular weight forms of Cx43, in
non-reducing WB, suggests that EV-Cx43 is assembled
into hexameric structures (Fig. 1a). This is in accordance
with our previous report, wherein we characterized in
great detail Cx43-containing EVs (7).
To evaluate whether Cx43 enhances the EV uptake
by tumour cells, EVCx43 or EVCx43 were exogenously
loaded with luciferin, after which they were added to
4T1luc2 tumour cells, overexpressing the firefly luciferase
and endogenously expressing Cx43. We observed that
Cx43 in extracellular vesicles is cardioprotective
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the light emitted by 4T1luc2 cells incubated with intact
EVCx43 is 1.7-fold higher, compared with that of cells
exposed to EVCx43 (Supplementary Fig. 1a), an effect
that is maintained in a dose-dependent manner (Supple-
mentary Fig. 1b). The levels of light emission after EV lysis
are similar in both populations of vesicles (Supplementary
Fig. 1a), suggesting that the same amount of luciferin
was loaded into EVs, regardless the presence of Cx43.
EVs loaded with dox are cytotoxic for tumour cells
in vitro
Then, we tested the efficiency of Cx43-containing EVs in
the delivery of dox to tumour cells. First, by fluorimetric
analysis, we demonstrated that a similar amount of dox
was incorporated into EVCx43 and EVCx43 (Fig. 1c).
Also, we showed that the electroporation procedure did
not compromise EV integrity (Fig. 1d), nor EV-Cx43 levels
(Supplementary Fig. 2a). To compare the cytotoxicity
of dox, equal amounts of dox (2 mM), either free or loaded
into EVCx43 or EVCx43 (EVCx43dox or EVCx43dox),
were added to recipient 4T1luc2 cells for 24 h. As control,
empty EVs were used. Results in Fig. 1e show a dramatic
decrease in cell viability after 24 h treatment with free dox,
an effect that was further enhanced in cells treated
with EVCx43dox, compared with their respective vehicle-
treated cells. However, no significant differences were found
between free dox and dox-loaded EVs, neither among
EVCx43dox nor EVCx43dox treatments. In addition, we
demonstrated that treatment with dox equally reduced the
metabolic activity of tumour cells (Fig. 1f), regardless the
delivery vehicle, in a dose-dependent manner (Supplemen-
tary Fig. 2b). The addition of empty EVs had no significant
alterations upon cell viability or metabolic activity.
EVs loaded with dox impair tumour cell proliferation
and motility in vitro
Next, we evaluated the effect of EV-dox in counteracting
the abnormal proliferation of tumour cells, by using
different complementary approaches (33). Results on
Fig. 2a show that the percentage of ki-67positive cells is
lower in the presence of EV-dox than the free drug.
Regarding the BrdU incorporation, a more pronounced
decrease was observed in cells treated with EVCx43dox
(Fig. 2b). This was further corroborated by the cell cycle
analysis, where treatment with EVCx43dox induced a cell
cycle arrest in G2/M phase, accompanied by a decrease
Fig. 1. EVs loaded with dox decrease the viability of tumour cells in vitro. (a) Characterization of EVs produced by HEK-293 cells
expressing or not Cx43 (EVCx43or EVCx43 ) was performed by WB under non-reducing conditions. The presence of EV markers CD63
and CD81 was analysed. Calnexin was used as control for cell debris contamination. Equal amounts of protein (10 mg) from total cellular
extracts from HEK-293Cx43 were used as control. (b) Representative TEM image of EVCx43 . Scale bars, 100 nm. (c) Ten micrograms of
EVCx43 or EVCx43 was loaded with 100 mg dox by electroporation; not incorporated dox was washed out with PBS by
ultracentrifugation. Values of EV-loaded dox (10% EV pellet) were quantified by fluorescence detection (emission, 594 nm; excitation,
480 nm) and are depicted in the graph. Fluorescence reading of similar amounts of free dox was used as control (n10). (d)
Representative TEM image of EVCx43dox after electroporation. Scale bars, 80 nm. (e) 4T1luc2 cells were treated with either 2 mM free dox
or dox loaded into EVs containing or not Cx43 (EVCx43dox and EVCx43dox) for 24 h. Equal amounts of EVCx43 or EVCx43 were
used for dox loading, and vehicle-treated cells were used as controls. Cell viability was assessed by flow cytometry analysis of propidium
iodide (PI) exclusion and by counting the number of Trypan blueexcluding cells. Number of viable cells is represented as percentage of
total cells (n3, *pB0.05 vs. CT, §pB0.05, §§pB0.01 vs. EVCx43 , ##pB0.01 ###pB0.001 vs. EVCx43 ). (f) Metabolic activity was
assessed by MTT reduction (n3, *pB0.05 vs. CT, §pB0.05 vs. EVCx43 , #pB0.05 vs. EVCx43 ).
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in the percentage of cells undergoing S-phase (Fig. 2c).
In colony formation assays, dox-loaded EVs presented
a similar effect as free dox, abolishing the clonogenic
potential of 4T1luc2 cells (Supplementary Fig. 2c). In
any circumstance, empty EVs did not present an effect.
Overall, despite that no statistical significance could be
achieved, dox loaded into EVs containing Cx43 presented
a trend toward an enhanced anti-proliferative capacity,
compared with either free dox or EVCx43dox.
Some of these data were confirmed in another tumour
cell line, MNNG/HOS, derived from an osteosarcoma.
The results obtained show that metabolic activity and cell
proliferation were impaired in the presence of either free
or EV-dox (Supplementary Fig. 2df). In parallel, to attest
whether this effect can be tumour specific, we evaluated
the same parameters in 2 non-tumour cell lines  kidney
epithelial HEK-293Cx43 cells and retinal pigment epithe-
lial Arpe-19 cells (Supplementary Fig. 3ac). Our data
show that, in this case, free dox leads to a significant
decrease in the metabolic activity, BrdU incorporation and
percentage of ki-67positive cells in both non-tumour cell
lines, whereas EV-dox presents minor toxicity to those
cells. Altogether, the data obtained with tumoural and
non-tumoural cell lines demonstrate that dox carried in
EVs, compared to free dox, is more toxic to tumour cells
and less toxic to non-tumour cells.
To prove that a functional channel is required to the
aforementioned effects, we used a Cx43 mimetic peptide,
gap26, that specifically blocks Cx43 channels (7,34).
Results in Fig. 2d show that, in the presence of gap26,
EVCx43dox were no longer able to impair proliferation
of recipient 4T1luc2 cells, whereas the use of gap26 showed
no effect upon treatment with EVCx43dox or free dox.
These data provide strong evidence that the increased
cytotoxicity of EVCx43dox can be, at least partially,
mediated by the function of Cx43 channels.
Furthermore, we evaluated cell motility, using time-
lapse microscopy. Our results show that 4T1luc2 cells
incubated with EVCx43dox present a significantly reduced
cell motility, compared to free dox treatment (Fig. 3a).
Given that mitogen-activated protein kinases are master
regulators of cell motility, survival and proliferation (35,36),
Fig. 2. EVs loaded with dox impair tumour cell proliferation in vitro. 4T1luc2 cells were treated with 2 mM free dox, EVCx43dox,
EVCx43dox or vehicles, for 24 h. (a) Representative images of ki-67 immunostaining (green). Nuclei were stained with 4,6-diamidino-2-
phenylindole (Dapi). Scale bars, 50 mm. Percentage of ki-67 (per total nuclei) is plotted in the graph (n3, *pB0.05 vs. CT, §§§pB0.001
vs. EVCx43 , ###pB0.001 vs. EVCx43 ). (b) Cell proliferation was assessed by the BrdU assay. Treatment with epidermal growth factor
(100 ng/ml, 24 h) was performed as positive control. Percentage of BrdU incorporation is plotted on the graph (n3, ##pB0.01 vs.
EVCx43 ). (c) Cell cycle analysis was performed by flow cytometry, using PI (n3). (d) 4T1luc2 cells were treated with 2 mM free dox,
EVCx43dox, EVCx43dox or vehicles, for 1 h. A Cx43-mimetic peptide (gap26, 0.25 mg/ml) was used, where indicated. Fresh media was
added and the cells cultured for an additional 23 h. Cell proliferation was assessed by the BrdU incorporation assay (n3, *pB0.05 vs.
CT, #pB0.05 vs. EVCx43 , §pB0.05 vs. EVCx43dox).
Cx43 in extracellular vesicles is cardioprotective
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we explored the effect of dox administration upon modula-
tion of the p44/42 pathway. Results in Fig. 3b show a
decreased activation of the p44/42 pathway in tumour cells
treated with either free or EV-dox for 24 h; this decrease
is only statistically significant when EVCx43dox are used.
Altogether, these data suggest that the anti-proliferative
effects and disruption of cell motility in response to
EVCx43dox treatment involve a downregulation of the
p44/42 pathway.
DOX loaded in EVs present therapeutic potential
identical to free dox in vivo
Once we established the anti-tumoural effect of dox loaded
in EVs in vitro, we proceeded to the in vivo studies.
We started by quantitatively assessing the communication
between EVs and tumour cells by using a subcutaneous
mouse xenograft model with bilateral flank tumours.
For that, we injected the mice i.t. with luciferin-loaded
EVCx43 or EVCx43 in opposed tumours of the same
animal. Results depicted in Supplementary Fig. 4 show
that EVCx43 were more efficient in the delivery of
luciferin to the tumours, as indicated by the 2.7-fold
increase in the signal, relative to EVCx43 . Because BLI of
animals receiving luciferin i.p. showed tumours with a
similar signal intensity, our data support the hypothesis
that the presence of Cx43 in EVs facilitates the release
of intraluminal content into target tumour cells.
To investigate the therapeutic potential of Cx43-
containing EVs in vivo, tumour-bearing mice received
treatment with equal amounts of dox (0.2 mg/kg i.t.;
Supplementary Fig. 5a), administered either free or
encapsulated in EVs (EVCx43dox or EVCx43dox),
5 and 8 days post-implantation of 4T1luc2 cells. As controls,
we used vehicle-treated animals  injected i.t. with either
PBS, EVCx43 or EVCx43 at the same concentrations.
Tumour response to different forms of treatment was
monitored by BLI, 11 days after cell inoculation. Treatment
of mice with EVCx43dox or EVCx43dox resulted in
anti-tumoural effects similar to the free drug (Fig. 4a).
In addition, we assessed tumour volumes using a manual
caliper (Fig. 4b) and determined the weight of excised
tumours (Fig. 4cd). Altogether, and considering the
comparison between dox-treated animals and their respec-
tive vehicles, we show that similar anti-tumoural effects
were obtained for free dox and dox encapsulated in
EVCx43 , whereas a better therapeutic efficiency was
observed for EVCx43dox, compared with EVs devoid of
Cx43. The effect of dox-induced apoptosis was also
evaluated through the analysis of Bax and Bcl2 levels in
tumours after the treatments (37). Results on Fig. 4e show
that only EVCx43dox induced a statistically significant
increase in the ratio Bax/Bcl2. In all the evaluated
parameters, injection of empty EVs produced no effect
and was therefore omitted from subsequent experiments.
Fig. 3. Cx43-containing EVs loaded with dox decrease the activation of signalling pathways related to cell motility. The 4T1luc2 cells were
treated with 2 mM free dox, EVCx43dox, EVCx43dox or vehicles, for 24 h. (a) Time-lapse microscopy was performed to assess cell
motility, followed by individual cell tracking. Mean distance and velocity are plotted in the graph (n3, ###pB0.001 vs. EVCx43 ;
*pB0.05 EVCx43dox vs. dox;). Left panel shows representative images of the assay. Scale bar, 10 mm. (b) Activation of the p44/42
pathway was analysed by WB. Calnexin was used as loading control (n3, #pB0.05 vs. EVCx43 ).
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Herein, the term vehicle is used to designate animals that
received treatment with PBS.
Subsequently, we evaluated the therapeutic value of
EVs concerning the tumour growth rate, by BLI. Similar
to the data presented above, dox-loaded EVs showed the
same therapeutic activity as free dox, inducing a pro-
gressive decrease in tumour growth rate relative to the
vehicle (Fig. 5ab). Despite no statistical differences, a
trend toward an increased efficiency for EVs containing
Cx43 (comparing with EVCx43dox) was maintained.
Representative images illustrating treatment with empty
EVs are presented in Supplementary Fig. 5b.
Cx43-containing EVs loaded with dox ameliorate dox
cardiotoxicity in vivo
Given the cardiotoxicity associated with dox-based thera-
pies, we sought to assess whether EVs are able to mitigate
such side effects in our model. To address this question,
we evaluated different parameters usually implicated in
dox cardiotoxicity, including oxidative stress and altered
expression of cardiac-specific genes (12,27,35,36,45). Al-
though HE staining showed no major histopathological
changes, transverse diameter of the cardiomyocytes was
reduced in the hearts of mice that received treatment with
free dox, an effect that was prevented upon EVCx43dox
treatment (Fig. 6a, upper panel). Moreover, free dox
treatment lead to increased myocardial fibrosis that was
not observed in animals that received dox encapsulated
in EVCx43 (Fig. 6a, bottom panel).
Dox-induced oxidative stress in the heart is mediated
by the activity of COX-2, that is, the generation of
reactive oxygen species responsible for the induction of
small heat shock proteins (3840). Our results show that
mice treated with free dox presented increased levels of
COX-2 and Hsp25 in the heart (Fig. 6bc), whereas
in those mice that received dox encapsulated in Cx43-
containing EVs, the cardiac levels of these proteins
remained unaltered.
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Fig. 4. EVs loaded with dox have anti-tumoural activity in 4T1luc2 tumour-bearing mice. Tumour-bearing mice were treated (i.t.) with
0.2 mg/kg of free dox, EVCx43dox or EVCx43dox or vehicles, on days 5 and 8 after subcutaneous inoculation of 4T1luc2 cells into
opposed flanks. Equal amounts of EVs were used in each condition. (a) Representative BLI of mice 11 days after 4T1luc2 cells inoculation,
corresponding to 3 days after the last treatment. (b) Tumour diameters were measured with a caliper, followed by determination of tumour
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Several cardiomyopathies have been associated with
GJ remodelling, which is accompanied by alterations
of the levels and/or subcellular distribution of Cx43, the
more abundant GJ protein in the myocardium (28,41).
Results depicted in Fig. 6d show that free dox lead to a
marked increase in the levels of Cx43 in the heart, which
was prevented by EVCx43dox treatment. Concerning
the animals treated with EVCx43dox, they presented an
intermediate phenotype, with an upregulation of COX-2
and Cx43, but not of Hsp25, and induction of fibrosis.
Altogether, these results demonstrate that i.t. admin-
istration of dox causes morphological and molecular
alterations in the heart that can partially be attenuated
using EVCx43 as a delivery vehicle of dox.
Discussion
It has become increasingly evident that EVs are major
conveyors of biological information between cells, making
them appealing candidates for directed drug delivery.
Although various studies have shown that these endogen-
ous vesicles can be used to deliver therapeutic cargo to
specific tissues (46), we are still far from reaching the
standardization needed to translate those evidences into
the clinical arena. Indeed, many drawbacks, including
some lack of specificity of EV to desirable target cells,
causing adverse effects, have hampered the enthusiasm
around of EV-based therapeutics. Therefore, the develop-
ment of strategies that aim to improve the efficacy of using
EVs as drug delivery systems with decreased side effects
are vital to boost this highly promising field of research. In
the present report, we show that EVs can be successfully
used to deliver dox to tumour cells in vitro and in vivo, ren-
dering a similar chemotherapeutic effect to that of the free
drug. More importantly, we demonstrate that the presence
of Cx43 in EVs potentially increases the therapeutic value
of these vesicles by reducing the cardiotoxicity of dox.
Despite the theoretical high potential of EVs as dox
vehicles for anti-tumour therapy, only 1 study from Tian
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et al. has shown that exogenous loading of dox into
exosomes can be used to inhibit tumour growth, using a
breast cancer mice model (10,40). Therefore, the results
gathered in our report constitute an important step
forward in favour of EVs as suitable delivery vehicles.
In addition, we provided important insights regarding the
mechanisms whereby dox-loaded EVs exert therapeutic
effects, showing that EV-dox impair metabolic activity and
proliferation of tumour cells in vitro, cause cell cycle arrest
and impair clonogenic ability of 4T1luc2 cells.
Concerning the donor cell type for vesicle production,
we used EVs from HEK-293 cells. HEK-293 cells have
been shown to be suitable for the delivery of other
therapeutic compounds in different animal models of
disease, including models of cancer and hepatic disorders
(10,11).
The more challenging step of targeted drug delivery is
still the design of vesicles with enhanced tropism to tumour
cells. For example, Ohno et al. demonstrated that the
miRNA let-7A can be successfully delivered by exosomes
displaying an epidermal growth factor receptor ligand,
leading to growth inhibition of breast cancer xenografts (4).
It was also demonstrated that the presence of iRGD
peptides at the exosomal surface increase the efficiency of
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dox delivery to tumour cells by targeting upregulated
integrin receptors, with a concomitant decrease of toxicity
to non-target organs (10). Because the expression of Cx43
in tumour and stromal cells can correlate with the
malignancy and metastatic potential of tumours (42), it
is conceivable that Cx43 constitutes a suitable target to
direct therapeutic vesicles, within specific types and/or
stages of tumour development. In the present study,
we show that the presence of Cx43 in EVs increases the
delivery efficiency of small compounds, such as luciferin,
into luciferase-expressing tumour cells, in vitro and in vivo.
Although the presence of Cx43 in EVs did not show a
statistically significant difference in terms of therapeutic
effect of dox, in the majority of the evaluated parameters
there is a clear trend for EVCx43 to present a better anti-
tumoural performance, compared to EVCx43 .
Moreover, the fact that the specific hemichannel in-
hibitor gap26 was able to prevent the effect of EVCx43dox
on cell proliferation impairment, underpins our model
in which functional Cx43 channels are required for the
cytotoxicity of EVCx43dox. This lead us to propose that,
in addition to endocytosis and membrane fusion of EVs
with recipient cells, an alternative and/or complementary
mechanism, involving the docking of Cx43 channels
present in both EVs and cells, can contribute for a more
efficient and/or rapid communication between recipient
cells and EVs (43). This can be relevant, for example,
to bypass inflammasome activation or rapid lysosomal
degradation of intraluminal cargo, thus improving the
value of EVs as therapeutic carriers (3).
In line with a previous study (13), our data show that
cardiac damage, induced by treatment of tumour-bearing
mice with free dox (i.t.), including morphological altera-
tions, increased fibrosis and upregulation of oxidative stress
response, can be attenuated when dox is carried by Cx43-
containing EVs, whereas delivery through EVCx43 did
not ameliorate dox cardiotoxicity. Given that in physiologi-
cal conditions, in the heart, Cx43 is mainly present at the
intercalated discs, forming GJ, these fully assembled chan-
nels would not be available to dock with Cx43 channels
present at the EV membranes, which could, at least partially,
explain our results. In contrast, EVs devoid of Cx43 would
be preferentially taken up by endocytosis and/or fusion, still
causing some degree of toxicity to the heart. Alternatively,
it is plausible that Cx43-containing EVs can be retained in
other organs and do not reach the heart.
In agreement with a recent report (44), we found that
free dox lead to an upregulation of Cx43, an effect that is
absent from hearts of animals treated with EVCx43dox.
Although in our study, we did not explore in detail the
subcellular distribution of cardiac Cx43, it is conceivable
that after dox exposure Cx43 accumulates at the inter-
calated discs, thus accounting for an increased intercellular
communication that could have a detrimental effect not
only through alterations to the electrical conduction system
required for synchronous heart contraction, but also by
contributions to the spread of damage signals, which,
in this case, would exacerbate dox-induced cardiotoxicity.
Overall, our results constitute an important contribu-
tion to reinforce the emerging and very promising idea
that EVs constitute an efficient drug delivery vehicle
for anti-tumoural therapeutic approaches. Moreover,
we provide strong evidence that the presence of Cx43 in
dox-containing EVs can reduce cardiotoxicity, without
compromising its therapeutic efficiency.
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